Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Will Ver­tex’s “pipeline-in-a-prod­uct” pay off?

That’s the bet be­hind the com­pa­ny’s $4.9 bil­lion ac­qui­si­tion of Alpine Im­mune Sci­ences and its mid-stage IgA nephropa­thy drug, which is de­signed to in­hib­it two key cy­tokines.

The com­pa­nies an­nounced the deal last week, tout­ing povetaci­cept’s po­ten­tial in IgA nephropa­thy (IgAN) and hint­ing at its broad­er am­bi­tions to treat au­toim­mune con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.